Treatment of chronic hepatitis B and drug resistance

Khalil Nazzal

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2009
vol. 4

Send email

Copy url:

abstract:

Review paper

Treatment of chronic hepatitis B and drug resistance

Khalil Nazzal

Przegląd Gastroenterologiczny 2009; 4 (1): 7–11

Online publish date: 2009/03/16

View full text Get citation

For more than ten years standard therapy of chronic hepatitis B was limited to interferon-a and lamivudine. Interferon-a is known to have several adverse effects, while the use of lamivudine is associated with HBV (hepatitis B virus) mutations. New nucleoside/nucleotide analogues have been registered during the last few years. New antiviral agents with different mechanisms of action than that of nucleotide/nucleoside analogues should be used in the future to achieve the optimal goal of therapy: the total eradication of HBV infection.

keywords:

Treatment of chronic hepatitis B and drug resistance

Khalil Nazzal

hepatitis B, nucleoside analogue, therapy, mutation, drug resistance